Exhibit 99.1

PHARMACYTE BIOTECH, INC.

SUPPLEMENT DATED JUNE 4, 2021 TO DEFINITIVE PROXY STATEMENT DATED MAY 5, 2021

FOR THE 2021 ANNUAL MEETING OF SHAREHOLDERS

TO BE HELD ON WEDNESDAY, JUNE 16, 2021

This supplement, dated June 4, 2021 (the “Supplement”), amends and supplements our proxy statement (“Proxy Statement”) filed with the Securities and Exchange Commission as an exhibit to our Current Report on Form 8-K on May 5, 2021 regarding the 2021 Annual Meeting of Shareholders (“Annual Meeting”) of PharmaCyte Biotech, Inc. (“Company”). As a reminder, the Company’s Annual Meeting will be held virtually at https://www.virtualshareholdermeeting.com/PMCB2021 on Wednesday, June 16, 2021 at 11:00 a.m., Pacific Daylight Time. This Supplement is being filed as an exhibit to our Current Report on Form 8-K filed June 4, 2021.

Except as amended or supplemented by this Supplement, all information set forth in the Proxy Statement remains unchanged and should be considered in casting your vote by proxy or in person at the Annual Meeting.

The purpose of this Supplement is to update the Proxy Statement regarding “What constitutes a quorum?”. Under the Company’s Amendment No. 3 to the Bylaws filed as an exhibit to our Current Report on Form 8-K filed June 4, 2021, (“Bylaws”), the holders of one-third of the outstanding shares of common stock as of the record date for the Annual Meeting are needed to constitute a quorum, permitting the Annual Meeting to conduct its business. As of the record date, there were 2,385,125,674 shares of common stock outstanding. Thus, the presence of holders representing at least 795,041,892 shares will be required to establish a quorum.

This Supplement does not change the proposals to be acted upon at the Annual Meeting, which are described in the Proxy Statement. If you have already submitted your proxy, you do not need to take any action unless you wish to change your vote.

Except as specifically supplemented by the information contained herein, all information set forth in the Proxy Statement remains unchanged. From and after the date of this Supplement, all references to the “Proxy Statement” included in the Proxy Statement are to the Proxy Statement as supplemented hereby. The Proxy Statement contains important information and this Supplement should be read in conjunction with the Proxy Statement.

Exhibit 99.2

AMENDMENT NO. 3 TO THE BYLAWS

OF

PHARMACYTE BIOTECH, INC.

September 20, 2018

Pursuant to Article 8 of the Amended and Restated Bylaws (the “Bylaws”) of PharmaCyte Biotech, Inc., a corporation organized and existing under the laws of the State of Nevada (the “Corporation”), the Corporation hereby certifies that:

ONE: The Bylaws are hereby amended by this Amendment as follows:

Article 4, Section 2 is hereby deleted in its entirety and replaced with the following:

“Section 2. ANNUAL MEETINGS. The annual meeting of the Shareholders shall be held at such time and place as may be designated from time to time by the Board of Directors for the purpose of electing directors and for the transaction of such other business as may properly be brought before the meeting.”

Article 4, Section 8 is hereby deleted in its entirety and replaced with the following:

“Section 8. QUORUM. The holders of one-third (1/3) of the voting power of the Corporation’s stock entitled to vote, present in person, or represented by proxy, shall constitute a quorum at all meetings of the Shareholders for the transaction of business except as otherwise provided by law, by the Articles of Incorporation, or by these By-Laws. If, however, such quorum shall not be present or represented at any meeting of the Shareholders, the shareholders entitled to vote, present in person, or represented by proxy, shall have the power to adjourn the meeting from time to time, until the requisite amount of voting power shall be present. At such adjourned meeting at which the requisite amount of voting power shall be represented, any business may be transacted which might have been transacted at a meeting as originally notified.

If a quorum be initially present, the Shareholders may continue to transact business until adjournment, notwithstanding the withdrawal of enough Shareholders to leave less than a quorum, if any action taken is approved by a majority of the voting power required to initially constitute a quorum.”

TWO: Except as expressly amended by the terms of this Amendment, all the terms and provisions of the Bylaws shall remain in full force and effect, and shall not be deemed modified, altered, or otherwise affected by this Amendment.

THREE: This Amendment has been duly adopted in accordance with the provisions of Article 8 of the Bylaws by the Board of Directors of the Corporation.

IN WITNESS WHEREOF, the Corporation has caused this Amendment to be signed by its Chief Executive Officer as of the date first written above.